Table 2

Details of contemporary HCC risk scores

Risk scoreComponentsOriginal cohortValidation (V)/performance (P)
LSM-Based Model (2013)56

  • Age

  • Gender

  • HBV DNA

  • LSM

  • Asian cohort (mixed treatment status)

  • V; none in other cohorts

LSM-HCC (2014)57

  • Age

  • Albumin

  • HBV DNA

  • LSM

  • Asian cohort (mixed treatment status)

Modification of CU-HCC:

  • V: Asian cohorts (mixed treatment status)59 60

  • P: superior to conventional risk scores and PAGE B,60 similar to mREACH-B59 60

mREACH-B (2014)58

  • Age

  • Gender

  • ALT

  • HBeAg status

  • LSM

  • Treated Asian cohort

Modification of REACH-B:

  • V: Asian cohorts (mixed treatment status)48 59 60

  • P: superior to conventional risk scores48 59and contemporary risk scores59 60

PAGE-B (2016)51

  • Age

  • Gender

  • Platelets

  • Treated Caucasian cohort

  • V: treated Asian cohorts52 54 60

  • P: similar or superior to conventional risk scores,52 similar to mPAGE-B54 60 but inferior to LSM-HCC and mREACH-B60

mPAGE-B (2018)53

  • Age

  • Gender

  • Platelets

  • Albumin

  • Treated Asian cohort

Modification of PAGE-B:

  • V: treated Asian cohort54

  • P: similar or superior to conventional risk scores54

  • ALT, alanine aminotransferase; CU-HCC, cumulative HCC; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; HCC, hepatocellular carcinoma; LSM, liver stiffness measurement; mPAGE-B, modified PAGE-B.